milrinone - Generic mfg.
Entresto (sacubitril/valsartan) - Novartis, ROVI Pharmaceuticals Laboratories
The hemodynamic effects of sacubitril/valsartan in the first 24 h of initiation in pediatric cardiac intensive care unit patients: insights using high-fidelity data. (PubMed, Pediatr Cardiol) - Sep 25, 2026 - "Linear mixed effects models were used to estimate post-initiation trends in absolute units from 2 to 24 h, accounting for repeated measures within patients and adjusting for age, ventricular assist device status, milrinone exposure, and circulatory physiology. Sacubitril/valsartan initiation in critically ill children is associated with coordinated changes in arterial, venous, and tissue-level physiology consistent with improved systemic oxygen delivery. The response appears continuous, with variability in magnitude across patients rather than discrete phenotypes." 
Journal • Critical care • Pediatrics
http://www.ncbi.nlm.nih.gov/pubmed/42782309
 
Adam Morrison; Agnes Szarek; Erika Mejia; Krysta Walter; Oscar Dominguez; Rohit S Loomba; Wesam Sourour
 
Sep 25, 2026
 
Prev Next